MedaRed is a biotechnology company focused on discovering and developing new therapeutics targeting fibrin. The company is founded upon the pioneering work of Dr. Katerina Akassoglou, who discovered that fibrin is implicated in the toxic inflammation that damages neurons in neurological diseases including Alzheimer's disease and multiple sclerosis.